23; right 36, 13, and 27); superior frontal gyrus (left Ϫ9, 31, and 45; right 17, 35, and 37). 17. Although the improvement in WM performance with cholinergic enhancement was a nonsignificant trend in the current study (P ϭ 0.07), in a previous study (9) with a larger sample (n ϭ 13) the effect was highly significant (P Ͻ 0.001). In the current study, we analyzed RT data for six of our seven subjects because the behavioral data for one subject were unavailable due to a computer failure. The difference in the significance of the two findings is simply a result of the difference in sample sizes. A power analysis shows that the size of the RT difference and variability in the current sample would yield a significant result (P ϭ 0.01) with a sample size of 13. During the memory trials, mean RT was 1180 ms during placebo and 1119 ms during physostigmine. During the control trials, mean RT was 735 ms during placebo and 709 ms during physostigmine, a difference that did not approach significance (P ϭ 0.24), suggesting that the effect of cholinergic enhancement on WM performance is not due to a nonspecific increase in arousal.18. Matched-pair t tests (two-tailed) were used to test the significance of drug-related changes in the volume of regions of interest that showed significant response contrasts.